Uterine Bleeding. Abnormal Uterine and Vaginal bleeding Unspecified
Conditions
Interventions
Intervention 1: The intervention group will receive Capsella bursa-pastoris capsule 2 g every 8 hours In the first 7 days of each cycle for 3 Month. Intervention 2: The control group will receive Mefe
Treatment - Drugs
The intervention group will receive Capsella bursa-pastoris capsule 2 g every 8 hours In the first 7 days of each cycle for 3 Month.
The control group will receive Mefenamic Acid Capsule 500 mg every 8 hours In the first 7 days of each cycle for 3 Month.
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Women aged 18 to 40 years old; Passing at least 3 months from IUD insertion; Heavy bleeding in menstrual cycles Due to the IUD insertion; Having regular menstrual cycles before IUD insertion; without disorders of the mefenamic acid consumption; Desire to participation in the study; Being literate Exclusion Criteria: Known uterine fibroids and other pathologies; Hypothyroid; Hyperthyroid; Coagulation problems and known diabetes.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of menstrual bleeding. Timepoint: Before intervention, 1, 2 and 3 months after intervention. Method of measurement: Hygam chart.;The duration of menstrual bleeding. Timepoint: Before intervention, 1, 2 and 3 months after intervention. Method of measurement: Hygam chart.;Severity of Menstrual pain. Timepoint: Before intervention, 1, 2 and 3 months after intervention. Method of measurement: VAS. | — |
Secondary
| Measure | Time frame |
|---|---|
| Female sexual function. Timepoint: Before intervention and 3 months after intervention. Method of measurement: FSFI questionnaire.;Adverse events. Timepoint: 1, 2 and 3 months after intervention. Method of measurement: Checklist. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed